Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Subspecialty Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Subspecialty Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Prevention

Preventing Colorectal Neoplasia Methods: Means and Myths

John Potter
John Potter
Fred Hutchinson Cancer Research Ctr., Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 2007
  • Article
  • Info & Metrics
Loading
AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

Abstract

CN04-01

Colorectal cancer (CRC) is the third most common cause of cancer death after lung and stomach cancer, with approximately 1 million new cases and over half a million deaths, worldwide, each year. This cancer shows 20- to 30-fold variation in age-adjusted rates internationally, the age-specific rates at older ages show several hundred-fold variation, and incidence rates can change very rapidly over time. The highest rates of CRC in the world are in Japan. The degree of difference from place to place and the rapidity of change over time are explainable, not by genes, but by changes in the environment - or perhaps by their interaction.
Rare familial forms of CRC are due to deleterious mutations in known and unknown genes; nonetheless, the large majority of CRC is not associated with a known inherited genetic lesion or even a strong family history. Known environmental factors increase risk (e.g., meat, smoking) and others reduce risk (e.g., vegetables, folate, aspirin, post-menopausal hormones, calcium and vitamin D). Many less dramatic genetic changes (polymorphisms) are relevant only in the presence of environmental factors.
In 1980, we proposed that estrogens would reduce risk of colon cancer and subsequently showed that, indeed, oral contraceptives and higher parity were associated with lower risk of colon cancer. The results of the Women’s Health Initiative trial show that PMH prevents CRC: more than 2 decades from original hypothesis to confirmation in a clinical trial.
The role of aspirin and other NSAIDs in lowering risk of CRC is well established, beginning with observations in animals, through the study showing that NSAIDs were effective even in FAP patients, to the results of randomized clinical trials of prevention of metachronous polyps. NSAIDs consistently lower risk of polyps and cancer in average-, moderate-, and high-risk individuals; longer duration of use predicts lower risk; and risk resumes after use is stopped.
Despite the emergence of clear evidence for the chemopreventive capacity of specific agents, the implementation of preventive regimens is problematic because of: differences in risk in the population, determined by age, genetic inheritance, lifestyle, and history; differences between the sexes; differences in effectiveness of agents; differences in the timing of use across the lifespan; and differences in the acceptable degree of possible harm.
Primary prevention by weight control and physical activity and secondary prevention by screening, early detection, and polypectomy contribute significantly to the ability of populations and individuals to lower their risk of CRC; the duration of protection following screening by sigmoidoscopy may be as long as 15 years or more.

Footnotes

  • First AACR Centennial Conference on Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

  • American Association for Cancer Research
Back to top
Clinical Cancer Research: 13 (22 Supplement)
November 2007
Volume 13, Issue 22 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preventing Colorectal Neoplasia Methods: Means and Myths
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Preventing Colorectal Neoplasia Methods: Means and Myths
John Potter
Clin Cancer Res November 15 2007 (13) (22 Supplement) CN04-01;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preventing Colorectal Neoplasia Methods: Means and Myths
John Potter
Clin Cancer Res November 15 2007 (13) (22 Supplement) CN04-01;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Prevention

  • Cyclin D1 as a Target for Cancer Chemoprevention
  • The effect of cyclooxygenase-2 inhibition on arachidonic acid metabolism in cancer cell lines
Show more Cancer Prevention

Cancer Prevention: Oral Presentations - Invited Abstracts

  • Cyclin D1 as a Target for Cancer Chemoprevention
Show more Cancer Prevention: Oral Presentations - Invited Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement